Polyarticular juvenile idiopathic arthritis
MONDO:0018456Also known as: juvenile polyarthritis, juvenile polyarticular arthritis, polyarticular JIA
40 clinical trials for this condition and its sub-types, 14 tagged with Polyarticular juvenile idiopathic arthritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Polyarticular juvenile idiopathic arthritis
-
New combo therapy shows promise for kids with stubborn arthritis
Disease control CompletedThis study tested whether adding leflunomide to standard methotrexate treatment helps children with polyarticular juvenile idiopathic arthritis (JIA) that did not improve with methotrexate alone. Fifty children were randomly assigned to receive either the combination or methotrex…
Phase 4 • Sponsor: Bangladesh Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Weekly shot may halt arthritis progression in kids
Disease control CompletedThis study tested whether a weekly injection of abatacept (Orencia) plus usual care could prevent juvenile idiopathic arthritis (JIA) from spreading to more joints or causing eye inflammation. 121 children with recent-onset JIA affecting 4 or fewer joints took part. The goal was …
Phase 3 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New IV drug shows promise for kids with stubborn arthritis
Disease control CompletedThis study tested an intravenous drug called golimumab in 130 children with active juvenile idiopathic arthritis that did not improve with methotrexate. The main goal was to measure how the drug moves through the body over time. The study was completed and provides information on…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Arthritis drug tested for Long-Term safety in kids
Disease control CompletedThis study looked at the long-term safety of the drug tocilizumab (Actemra) in 7 children with a type of arthritis called juvenile idiopathic arthritis. All children had already completed a previous study and continued to receive the drug every 4 weeks for up to 2 years. The main…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC